Dong Zhen, Lei Qian, Liu Lichao, Cui Hongjuan
College of Biotechnology, State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, China.
Department of Dermatology, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei, China.
Sheng Wu Gong Cheng Xue Bao. 2016 Jul 25;32(7):870-879. doi: 10.13345/j.cjb.150403.
As a member of the sirtuins family, also called Class III histone deacetylases (HDACs), SIRT6 has many catalytic enzyme activities and plays a pivotal role in biological processes including anti-aging, chromatin regulation, transcriptional control, glucose and lipid metabolism, and DNA damage repair. Recently, increasing evidences indicated that SIRT6 was related to initiation and development of tumors, such as hepatic cancer, lung cancer, breast cancer and genital system tumors. However, SIRT6 might play a dual role in tumorigenesis and progression. SIRT6 often acted as a tumor suppressor, but might play an oncogenic role. Based on our current study, we depicted the essential roles of SIRT6 in the initiation and progression of various tumors, and summarized its mode of actions, which might provide clues for cancer therapy.
作为沉默调节蛋白家族（也称为Ⅲ类组蛋白去乙酰化酶（HDACs））的一员，SIRT6具有多种催化酶活性，在包括抗衰老、染色质调节、转录控制、葡萄糖和脂质代谢以及DNA损伤修复等生物学过程中发挥着关键作用。最近，越来越多的证据表明，SIRT6与肿瘤的发生和发展有关，如肝癌、肺癌、乳腺癌和生殖系统肿瘤。然而，SIRT6在肿瘤发生和进展中可能发挥双重作用。SIRT6通常作为肿瘤抑制因子起作用，但也可能发挥致癌作用。基于我们目前的研究，我们描述了SIRT6在各种肿瘤发生和进展中的重要作用，并总结了其作用模式，这可能为癌症治疗提供线索。
